Nathan’s Story: VCP Disease and the need for a Rare Disease Advisory Council in Georgia

Since I was a freshman at Georgia Tech, I have had a clock ticking in my head.  Since my mother presented symptoms of the VCP gene mutation, I had grown up knowing that a rare disease existed in my family and that there was a 50% chance that I might get it as an adult in my 30’s to 40’s. My mother and aunt are both deceased from the disease, and I have two uncles (four out of six siblings) that possess the VCP gene mutation that was passed down from their mother.  Symptoms include muscle wasting, Paget’s disease of bone, frontotemporal dementia, ALS and Parkinson’s.  A patient can get any combination of symptoms and the disease is fatal.  For ten years, my mother could not walk, feed herself, bathe herself or go to the bathroom by herself and my dad was her primary care partner.  I know what my future holds, and my advocacy work is for my three boys.

I jumped at every career opportunity to advance as quickly as possible.  Some might even say I was reckless.  I quit a six-figure job and moved my wife and two sons at the time to Boston to attend grad school at MIT as I knew I might not get another shot.  My oldest son lived in six states by the time he was nine and I did everything I could do to advance professionally in the event that I was “lucky” enough to have the gene mutation.

In my late 30’s, after feeling weakness in my muscles and receiving my positive gene mutation diagnosis from a researcher in California, I visited the Emory neuromuscular center to request a nuclear bone scan.  There are no treatments for my disease except for Paget’s disease of bone, if detected early enough.  During that first appointment, the doctor looked at me and said that he had never heard of my disease and that it might all be in my head.  My wife and I spent the next 45 minutes educating him about what to expect with a VCP gene mutation to not much success.  It wasn’t until I visited the Emory ALS Clinic that I found a doctor familiar with my genetic mutation.  I am his only patient with my genetic mutation. In rare diseases, access to specialty and timely medical care is crucial and can save lives and the unnecessary costs. Because there may be only a few experts in the world, many patients do not receive the care that they need.

After leading multiple businesses, I am now on full disability as we were “blessed” that I made some wise financial decisions to protect my family. I am still somewhat independent now, but my disease is progressive so I will continue to lose strength, energy, and the ability to walk. My wife and children are having to take a larger share of things l feel I should do, like mow the lawn, clean the gutters, and get things from the attic. I wish I could still do dad things like teach my boys to play basketball or take them camping. I am blessed with a wonderful family, but my rare disease is a burden to them. Rare disease affects everyone in the family. One in 10 people have a rare disease, 50% are pediatric diseases and only 5% of rare diseases have a cure. Rare disease affects many families in Georgia.

Others are not so “blessed” as I have been, and it is vital that we protect and advocate for those affected by rare disease.  My wife and I started a rare disease non-profit, Cure VCP Disease , in 2018, headquartered in Americus, Georgia, in order to help make life better for other rare disease families. We have funded research, facilitated scientific collaborations, and established a supportive patient community.

There are over 7,000 rare diseases and rare disease is complex.  I’ve learned how complex it is only because I am an affected patient.  HB 918, which advocates for the creation of a Rare Disease Advisory Council in Georgia will be one voice that can aid legislators, policy makers and the general Georgia population, in making prudent decisions to support and help rare disease patients and care partners in Georgia.  Finding a cure and treatment for rare disease is only half the battle. How will it be administered and most importantly, how will it be paid for?  Those are only a few of the important issues that the Rare Disease Advisory Council can help advise the people and representatives of Georgia.

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS